December 9th, 2020
15:00 GMT / 16:00 CET / 10:00 EST
An increasing number of clinical laboratories are using next generation sequencing (NGS) for the molecular characterization of cancer. As NGS results grow in volume and complexity, and medical guidelines and evidence continue to evolve, decision support systems can facilitate the reporting of clinically relevant variants. In this talk, our speaker will discuss how software capable of automated annotation and presentation of clinically relevant information reduces the complexity of NGS results. Recent data on the usability and accuracy of such a software, NAVIFY Mutation Profiler, will also be presented.
Learning Objectives:
- Identify the challenges facing molecular geneticists and medical oncologists in working with results from NGS testing for somatic oncology
- Understand the considerations for implementing a decision support software in aiding the interpretation of clinically important variants
- Learn about recent results on the accuracy and usability of NAVIFY Mutation Profiler
